Introduction: Immune checkpoint inhibitors (ICIs) have improved lung cancer treatment but are associated with an increased risk of cardiotoxicity. We investigated whether statins could mitigate ICI-associated cardiovascular risks in lung cancer patients. Methods: We performed a retrospective, propensity score-matched cohort study utilizing the TriNetX database. We identified lung cancer patients receiving ICIs between April 2013 and June 2023. We created two cohorts: statin users and non-users. The primary efficacy outcome was major adverse cardiovascular events (MACE), defined as a composite of myocardial infarction, ischemic stroke, and heart failure. The secondary efficacy outcomes were myocarditis and cardiac arrest. Safety outcomes were all-cause mortality and serious immune-related adverse events (irAEs). Results: A total of 16,650 lung cancer patients undergoing ICIs were identified, consisting of 6,812 statin users and 9,838 non-users. After propensity score matching, 4,379 patients were well-matched in baseline characteristics. Over a follow-up period of 12 months, statin use was associated with a lower risk of MACE (HR: 0.87, 95% CI: 0.78–0.98), primarily driven by reductions in myocardial infarction (HR: 0.75, 95% CI: 0.58-0.97) and heart failure (HR: 0.85, 95% CI: 0.74–0.98). For safety outcomes, statin use was associated with a reduction in all-cause mortality (HR: 0.83, 95% CI: 0.77–0.90) and did not result in an increased risk of serious irAEs. Conclusion: The use of statins in lung cancer patients with cardiovascular risk factors and without previous cardiovascular events undergoing immunotherapy was associated with a reduction in MACE and all-cause mortality without an increased risk of serious adverse events.

1.
Tang
S
,
Qin
C
,
Hu
H
,
Liu
T
,
He
Y
,
Guo
H
, et al
.
Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects
.
Cells
.
2022
;
11
(
3
):
320
.
2.
Ball
S
,
Ghosh
RK
,
Wongsaengsak
S
,
Bandyopadhyay
D
,
Ghosh
GC
,
Aronow
WS
, et al
.
Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week
.
J Am Coll Cardiol
.
2019
;
74
(
13
):
1714
27
.
3.
Hu
JR
,
Florido
R
,
Lipson
EJ
,
Naidoo
J
,
Ardehali
R
,
Tocchetti
CG
, et al
.
Cardiovascular toxicities associated with immune checkpoint inhibitors
.
Cardiovasc Res
.
2019
;
115
(
5
):
854
68
.
4.
Lehmann
LH
,
Heckmann
MB
,
Bailly
G
,
Finke
D
,
Procureur
A
,
Power
JR
, et al
.
Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis
.
Circulation
.
2023
;
148
(
6
):
473
86
.
5.
Gergely
TG
,
Drobni
ZD
,
Sayour
NV
,
Ferdinandy
P
,
Varga
ZV
.
Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
.
Basic Res Cardiol
.
2025
;
120
(
1
):
187
205
.
6.
Li
X
,
Peng
W
,
Wu
J
,
Yeung
SCJ
,
Yang
R
.
Advances in immune checkpoint inhibitors induced-cardiotoxicity
.
Front Immunol
.
2023
;
14
:
1130438
.
7.
US Preventive Services Task Force
,
Mangione
CM
,
Barry
MJ
,
Nicholson
WK
,
Cabana
M
,
Chelmow
D
, et al
.
Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement
.
JAMA
.
2022
;
328
(
8
):
746
53
.
8.
Tabrizi
R
,
Tamtaji
OR
,
Mirhosseini
N
,
Lankarani
KB
,
Akbari
M
,
Dadgostar
E
, et al
.
The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials
.
Pharmacol Res
.
2019
;
141
:
85
103
.
9.
Endres
M
,
Laufs
U
.
Effects of statins on endothelium and signaling mechanisms
.
Stroke
.
2004
;
35
(
11 Suppl 1
):
2708
11
.
10.
Luan
Z
,
Chase
AJ
,
Newby
AC
.
Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages
.
Arterioscler Thromb Vasc Biol
.
2003
;
23
(
5
):
769
75
.
11.
Siniscalchi
C
,
Basaglia
M
,
Riva
M
,
Meschi
M
,
Meschi
T
,
Castaldo
G
, et al
.
Statins effects on blood clotting: a review
.
Cells
.
2023
;
12
(
23
):
2719
.
12.
Kim
YC
,
Kim
KK
,
Shevach
EM
.
Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction
.
Immunology
.
2010
;
130
(
4
):
484
93
.
13.
Neilan
TG
,
Quinaglia
T
,
Onoue
T
,
Mahmood
SS
,
Drobni
ZD
,
Gilman
HK
, et al
.
Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial
.
JAMA
.
2023
;
330
(
6
):
528
36
.
14.
Palchuk
MB
,
London
JW
,
Perez-Rey
D
,
Drebert
ZJ
,
Winer-Jones
JP
,
Thompson
CN
, et al
.
A global federated real-world data and analytics platform for research
.
JAMIA Open
.
2023
;
6
(
2
):
ooad035
.
15.
Arvanitis
M
,
Lowenstein
CJ
.
Dyslipidemia
.
Ann Intern Med
.
2023
;
176
(
6
):
Itc81
96
.
16.
Global Cardiovascular Risk Consortium
,
Magnussen
C
,
Ojeda
FM
,
Leong
DP
,
Alegre-Diaz
J
,
Amouyel
P
, et al
.
Global effect of modifiable risk factors on cardiovascular disease and mortality
.
N Engl J Med
.
2023
;
389
(
14
):
1273
85
.
17.
Lee
K
,
Kang
S
,
Hwang
J
.
Lung cancer patients’ characteristics and comorbidities using the Korean National hospital discharge in-depth injury survey data
.
J Epidemiol Glob Health
.
2022
;
12
(
3
):
258
66
.
18.
Cho
IY
,
Han
K
,
Shin
DW
,
Park
SH
,
Yoon
DW
,
Shin
S
, et al
.
Cardiovascular risk and undertreatment of dyslipidemia in lung cancer survivors: a nationwide population-based study
.
Curr Probl Cancer
.
2021
;
45
(
1
):
100615
.
19.
Mahmood
SS
,
Fradley
MG
,
Cohen
JV
,
Nohria
A
,
Reynolds
KL
,
Heinzerling
LM
, et al
.
Myocarditis in patients treated with immune checkpoint inhibitors
.
J Am Coll Cardiol
.
2018
;
71
(
16
):
1755
64
.
20.
Dolladille
C
,
Akroun
J
,
Morice
PM
,
Dompmartin
A
,
Ezine
E
,
Sassier
M
, et al
.
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis
.
Eur Heart J
.
2021
;
42
(
48
):
4964
77
.
21.
Darnell
EP
,
Mooradian
MJ
,
Baruch
EN
,
Yilmaz
M
,
Reynolds
KL
.
Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls
.
Curr Oncol Rep
.
2020
;
22
(
4
):
39
.
22.
Brahmer
JR
,
Abu-Sbeih
H
,
Ascierto
PA
,
Brufsky
J
,
Cappelli
LC
,
Cortazar
FB
, et al
.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
.
J Immunother Cancer
.
2021
;
9
(
6
):
e002435
.
23.
Das
S
,
Johnson
DB
.
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
.
J Immunother Cancer
.
2019
;
7
(
1
):
306
.
24.
Brookhart
MA
,
Schneeweiss
S
,
Rothman
KJ
,
Glynn
RJ
,
Avorn
J
,
Stürmer
T
.
Variable selection for propensity score models
.
Am J Epidemiol
.
2006
;
163
(
12
):
1149
56
.
25.
Zhang
Z
,
Kim
HJ
,
Lonjon
G
,
Zhu
Y
;
Written on behalf of AME Big-Data Clinical Trial Collaborative Group
.
Balance diagnostics after propensity score matching
.
Ann Transl Med
.
2019
;
7
(
1
):
16
.
26.
Ito
K
,
Murphy
D
.
Application of ggplot2 to pharmacometric graphics
.
CPT Pharmacometrics Syst Pharmacol
.
2013
;
2
(
10
):
e79
.
27.
Leise
MD
,
Poterucha
JJ
,
Talwalkar
JA
.
Drug-induced liver injury
.
Mayo Clin Proc
.
2014
;
89
(
1
):
95
106
.
28.
Statins
.
LiverTox: clinical and research information on drug-induced liver injury
.
Bethesda (MD)
:
National Institute of Diabetes and Digestive and Kidney Diseases
;
2012
.
29.
Drobni
ZD
,
Alvi
RM
,
Taron
J
,
Zafar
A
,
Murphy
SP
,
Rambarat
PK
, et al
.
Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque
.
Circulation
.
2020
;
142
(
24
):
2299
311
.
30.
van Rosendael
AR
,
Narula
J
,
Lin
FY
,
van den Hoogen
IJ
,
Gianni
U
,
Al Hussein Alawamlh
O
, et al
.
Association of high-density calcified 1K plaque with risk of acute coronary syndrome
.
JAMA Cardiol
.
2020
;
5
(
3
):
282
90
.
31.
US Preventive Services Task Force
,
Bibbins-Domingo
K
,
Grossman
DC
,
Curry
SJ
,
Davidson
KW
,
Epling
JW
Jr
, et al
.
Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement
.
JAMA
.
2016
;
316
(
19
):
1997
2007
.
32.
Taylor
F
,
Huffman
MD
,
Macedo
AF
,
Moore
THM
,
Burke
M
,
Davey Smith
G
, et al
.
Statins for the primary prevention of cardiovascular disease
.
Cochrane Database Syst Rev
.
2013
;
2013
(
1
):
Cd004816
.
33.
Mao
W
,
Cai
Y
,
Chen
D
,
Jiang
G
,
Xu
Y
,
Chen
R
, et al
.
Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer
.
JCI Insight
.
2022
;
7
(
18
):
e161940
.
34.
Zhang
L
,
Wang
H
,
Tian
J
,
Sui
L
,
Chen
X
.
Concomitant statins and the survival of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis
.
Int J Clin Pract
.
2022
;
2022
:
3429462
.
You do not currently have access to this content.